Skip to content
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
SideMenu
Home
Blog
Biosimilars Council Press Releases
Blog
Blog
April 16, 2024
AAM
Seniors Pay More for Generic Medicines Every Year While Prices Continue to Fall. Why?
Blog
February 22, 2024
AAM
Access! 2024 – Charting a Sustainable Path for Generics and Biosimilars
Blog
October 20, 2023
AAM
2023 Report
Blog
October 18, 2023
AAM
GRx+Biosims 2023 Conference Recap
Blog
September 13, 2023
AAM
Member Spotlight: Biocon Biologics
Blog
July 17, 2023
AAM
Pharmacy Benefit Managers Are Blocking Patient Access to Biosimilar Insulin
Blog
June 28, 2023
AAM
U.S. Patients Rely On Generic Medicines But Increases In Drug Shortages Reflect Challenges To Their Long-Term Sustainability
Blog
May 12, 2023
AAM
Associate Members Spotlight: Antheia
Blog
May 10, 2023
AAM
Shamekka Shares Why We Should Never Take Moms #4GRxANTED
Blog
February 24, 2023
AAM
A Look Back at Access! 2023
Blog
February 9, 2023
AAM
The Quickest Route to U.S. Essential Medicines Production: Existing and Idle Production Sites
Blog
January 5, 2023
AAM
Desi is Back Playing Soccer and Doing “Normal Kid” Stuff
Load More
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
About the Association
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Community Commitment
Careers
Contact Us
Resources
2025 Savings Report
2025 Advocacy Priorities
2025 First Generics White Paper
Drug Shortages White Paper
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Blog
Founders Blogs
Amicus Briefs
Patient Stories
Advocacy
Federal Advocacy
Biosimilars
GDUFA/BsUFA User Fees
Inflation Reduction Act
Intellectual Property & Patent Reform
Medicaid Generics Penalty
State Advocacy
Tariffs & Trade
Events
GRx+Biosims 2025
Access! 2026
Press Releases
JOIN
